...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >The active ingredients and mechanisms of Longchai Jiangxue Formula in treating PV, based on UPLC/Q-TOF-MS/MS, systematic pharmacology, and molecular biology validation
【24h】

The active ingredients and mechanisms of Longchai Jiangxue Formula in treating PV, based on UPLC/Q-TOF-MS/MS, systematic pharmacology, and molecular biology validation

机译:基于UPLC / Q-TOF-MS / MS,系统药理学和分子生物学验证,龙翼江苏公式治疗PV的活性成分及机制

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Polycythemia vera (PV) is a refractory hematological disease that lack of effective therapy. Chinese traditional medicine Longchai Jiangxue formula (LCJX) has showed the powerful effects on PV. However, the active ingredients and mechanisms of this formula have not been elucidated. We explored the active ingredients and mechanisms of LCJX for treating PV. Methods: The chemical constituents of LCJX were qualitatively analyzed by UPLC/Q-TOF-MS/MS. On this basis, the TCMSP, ETCM, PubChem BioAssay and ChEMBL databases were searched to predict the potential targets of chemical components of LCJX. Then Genecards, GEO, DisGeNET, and OMIM databases were used to retrieve data of targets related to PV. Drug-disease-target network and protein-protein-interaction (PPI) network were built. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed. Finally, Molecular docking, CCK-8 assay, Annexin V-FITC/PI staining and western blot were processed so as to screen the active components related to PV and elucidate its mechanisms. Results: A total of 84 compounds were identified from LCJX by UPLC/Q-TOF-MS/MS. After removed duplicate items, there were 143 targets linked to both disease and drugs. Crucial genes, such as MTOR, HIF1A, JAK2, VEGFA, STAT3, AKT1, TERT, MAPK1, were shown in PPI network. GO enrichment indicated that oxidative stress process, tyrosine kinase activity and phosphatase binding function, and cell membrane structure were in reference to LCJX against PV. KEGG enrichment showed that JAK-STAT signaling pathway and PI3K-Akt signaling pathway, were put in an important position of the treatment. Furthermore, Molecular docking, CCK-8 assay, Annexin V-FITC/PI staining and western blot technique proved the therapeutic effect of Saikosaponin A, main ingredient of LCJX. Conclusion: This study, combined with UPLC/Q-TOF-MS/MS, network pharmacology and molecular biology, provides a reference for the identification of effective components, screening of quality markers and analysis of its action mechanism of LCJX.
机译:背景:真性红细胞增多症(PV)是一种缺乏有效治疗的难治性血液病。中药龙柴降血方(LCJX)已显示出对PV的强大作用。然而,该配方的活性成分和机理尚未阐明。我们探索了LCJX治疗PV的有效成分和机制。方法:采用UPLC/Q-TOF-MS/MS定性分析LCJX的化学成分,在此基础上,检索TCMSP、ETCM、PubChem BioAssay和ChEMBL数据库,预测LCJX化学成分的潜在靶点。然后使用基因卡、GEO、DisGeNET和OMIM数据库检索与PV相关的目标数据。建立了药物-疾病靶点网络和蛋白质-蛋白质相互作用(PPI)网络。进行了基因本体(GO)和京都基因和基因组百科全书(KEGG)富集分析。最后,通过分子对接、CCK-8分析、Annexin V-FITC/PI染色和western blot,筛选与PV相关的活性成分并阐明其作用机制。结果:通过UPLC/Q-TOF-MS/MS从LCJX中鉴定出84个化合物。删除重复项目后,共有143个与疾病和药物相关的靶点。PPI网络中显示了关键基因,如MTOR、HIF1A、JAK2、VEGFA、STAT3、AKT1、TERT、MAPK1。GO富集表明氧化应激过程、酪氨酸激酶活性和磷酸酶结合功能以及细胞膜结构与LCJX对抗PV有关。KEGG富集显示JAK-STAT信号通路和PI3K-Akt信号通路在治疗中处于重要地位。此外,分子对接、CCK-8分析、Annexin V-FITC/PI染色和western blot技术证明了柴胡皂苷A(LCJX的主要成分)的治疗效果。结论:本研究结合UPLC/Q-TOF-MS/MS、网络药理学和分子生物学,为LCJX的有效成分鉴定、质量标志物筛选和作用机理分析提供了参考。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号